Latest Multiple Sclerosis News
HealthCentral.com Mon, 01 Oct 2007 5:46 PM PDT
Nontraditional methods of treating MS have been proven effective in slowing the disease. Click here to read more about how relaxation and mediations techniques, music therapy and yoga can help treat MS.
MS patient finds therapy in canes
Seattle Post-Intelligencer Mon, 01 Oct 2007 6:34 PM PDT
A multiple sclerosis patient has been carving walking canes and donating them to other patients as therapy for himself.

New Stroke Treatment Has Immediate Effects
Lex 18 - Lexington,KY,USA
Minocycline has already been shown to have a neuroprotective effect in animal models of multiple sclerosis, Parkinsons disease, Huntingtons disease, ...
See all stories on this topic

New Treatment for Stroke Leads to Fewer Disabilities
Associated Content - Denver,CO,USA
Other studies have shown that minocycline has already been shown to have an effect in animal models of multiple sclerosis, Parkinson's disease, ...
See all stories on this topic

Minocycline May Improve Stroke Outcomes
Medscape (subscription) - USA
... second-generation derivative of tetracycline, and has been shown to have a "clear beneficial protective effect," in animal models of multiple sclerosis, ...
See all stories on this topic

Sector Snap: Biotechnology
CNNMoney.com - USA
s Tysabri multiple sclerosis drug may be too high, and initiated coverage of the Irish biotechnology company with an "Underperform" rating on Tuesday. ...
See all stories on this topic

Broker Action For Tuesday, Oct. 2
Forbes - NY,USA
While both companies are optimistic about their sclerosis drug, Tysabri, an FBR analyst and a Credit Suisse analyst believe sales will be weaker than ...
See all stories on this topic

Drug stocks edge lower; ViaCell soars on buyout offer
MarketWatch - USA
Early Tuesday, analysts at FBR Research released a note questioning whether Biogen's sales and user estimates for its multiple sclerosis drug Tysabri were ...
See all stories on this topic

Genentech "outperform"
newratings.com - USA
The company's potential pipeline catalysts include Rituxan's phase 3 lupus data in 1H08, Rituxan's phase 3 PPMS data in 1H08 and Avastin's adjuvant colon ...
See all stories on this topic

• [Report] Multiple Sclerosis Market Research, Trends, Analysi...

  Phase I data show subcutaneous injection of CNT0-1275 is well tolerated ... Additional PPMS study in four patients shows Rituxan suppresses B-cells ...

  www.the-infoshop.com/study/dc50803-pipeline_toc.... - 44k - Similar pages

  http://www.the-infoshop.com/study/dc50803-pipeline_toc.html

• Multiple Sclerosis Quarterly Report » Blog Archive » MS ...

  Rituximab has been approved for treating non-Hodgkin’s B-cell lymphomas, ... Currently, a phase II/III trial for use of this drug in PPMS and a phase II ...

  www.unitedspinal.org/publications/msqr/?p=96 - 29k - Similar pages